Bio Pharma Dive
FEBRUARY 20, 2025
The $160 million acquisition of a FibroGen subsidiary expands AstraZeneca’s foothold in China while the company works through government investigations into its business practices there.
Pharmaceutical Technology
FEBRUARY 20, 2025
The FDA, NIH and CDC has cut 5,200 probationary staff in a job cull across the HHS over the Valentine's Day weekend.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
FEBRUARY 20, 2025
"Any place that gets cut, it's going to have an impact, because there's not any spare personnel at FDA,” said former agency commissioner Robert Califf.
Pharmaceutical Technology
FEBRUARY 20, 2025
ImmunityBio has gained the FDA authorisation for an EAP to supply an alternative source of BCG for treating bladder cancer.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
FEBRUARY 20, 2025
Originally scheduled for next week, the meeting of agency advisers will be delayed to give more time for public comment, according to an HHS spokesperson.
Pharmaceutical Technology
FEBRUARY 20, 2025
Zealands CEO Adam Steensberg said that the company is exactly where it wants to be in terms of its partnering and development timeline.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
FEBRUARY 20, 2025
AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney disease.
Pharma Times
FEBRUARY 20, 2025
Tenosynovial giant cell tumours can cause pain, stiffness, swelling and movement limitations
Pharmaceutical Technology
FEBRUARY 20, 2025
X4 has entered an exclusive agreement with taiba rare for distributing and commercialising Xolremdi in select Middle Eastern countries.
Bio Pharma Dive
FEBRUARY 20, 2025
Layoffs at the FDA’s device center could add “months, if not years” to the time it takes to bring products to market, an attorney said.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
FEBRUARY 20, 2025
In this review, GlobalData considers the products both approved and priced in 2024 and the factors that influenced their launch strategy.
Bio Pharma Dive
FEBRUARY 20, 2025
A Missouri district court judge said stopping the FTC’s suit against Caremark, Express Scripts and Optum Rx would be “against the public’s interest.
Pharmaceutical Technology
FEBRUARY 20, 2025
FDA has granted priority review for Boehringer Ingelheims zongertinib NDA for treating unresectable or metastatic NSCLC.
pharmaphorum
FEBRUARY 20, 2025
SMA treatment with Evrysdi 'could start prenatally' Phil.
Trialfacts
FEBRUARY 20, 2025
Contents About the Study Why Participate? Your Rights Who Can Participate? More Study Details About the Research Center Study Location Research Center: University of Maryland Baltimore Location: 419 W. Redwood St., Suite 470 Lead Researcher: Dr. Osamah Saeedi IRB: This study has been reviewed and approved by the University of Maryland IRB About the Study Vision changes can be a major concern, especially as we age, and researchers are studying how age-related cognitive changes may affect vision.
pharmaphorum
FEBRUARY 20, 2025
Boehringer Ingelheim's oral HER2 inhibitor zongertinib has started an FDA review as a lung cancer treatment with a decision due in the third quarter.
Pharmaceutical Commerce
FEBRUARY 20, 2025
FDA approves an expanded access program that would offer patients an alternative to Mercks bladder cancer medication.
pharmaphorum
FEBRUARY 20, 2025
Around 1,400 patients with Lennox-Gastaut Syndrome will be eligible for NHS treatment with UCB's Fintepla after a NICE recommendation
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Commerce
FEBRUARY 20, 2025
The latest news for pharma industry insiders.
pharmaphorum
FEBRUARY 20, 2025
Learn how incorporating storytelling techniques can humanise healthcare marketing and enhance patient engagement in "The 'Wicked' Prescription.
Pharmaceutical Commerce
FEBRUARY 20, 2025
In the third part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Laura Johnson, senior director of sales, life sciences, Loftware, discusses why the demand for supply chain transparency is continuing to gain momentum, while also explaining the role that track-and-trace initiatives are playing in that effort.
pharmaphorum
FEBRUARY 20, 2025
The rise and market race of anti-IL23p19 therapies in IBD: How ECCO 2025 readouts will shape the anti-interleukin landscape Mike.
Pharmaceutical Technology
FEBRUARY 20, 2025
The World Health Organization (WHO) said it will conduct another mass vaccination round in the Gaza Strip to protect children against polio.
pharmaphorum
FEBRUARY 20, 2025
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Helen Thackray, chief R&D officer at biotech company BioCryst, as well as an alumnus of the Childrens National Medical Center.
Drug Patent Watch
FEBRUARY 20, 2025
The Unseen Heroes of the Pharmaceutical Industry: Achieving High-Quality Standards in Generic Drugs As we navigate the complex world of healthcare, it's easy to overlook the unsung heroes who work tirelessly behind the scenes to bring affordable, high-quality medications to the masses. I'm talking about the generic drug manufacturers who play a vital role in making life-saving treatments accessible to people worldwide.
pharmaphorum
FEBRUARY 20, 2025
Around 600 people with various types of B-cell lymphoma will be eligible for treatment with BMS' CAR-T therapy Breyanzi under new NICE guidance.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
XTalks
FEBRUARY 20, 2025
On February 10, 2025, Sionna Therapeutics Inc. announced the successful closing of its upsized initial public offering (IPO). The Sionna Therapeutics IPO saw the company sell 12,176,467 shares of common stock at $18.00 per share including an additional 1,588,234 shares from the underwriters option. With gross proceeds of approximately $219.2 million (before deducting underwriting discounts, commissions and other expenses) Sionna has marked a major milestone in its growth journey.
Intouch Solutions
FEBRUARY 20, 2025
Rare and ultra-rare diseases face problems most brands do turned up to 11. Budgets? Smaller. Patient pool? Even smaller. Healthcare providers (HCPs) who understand the condition? Sometimes even smaller than that. Treatment options can be limited, access can be hard to find and diagnosis time can sometimes be measured in decades rather than months. Its a perfect storm.
XTalks
FEBRUARY 20, 2025
The pharmaceutical and biotechnology industry has kicked off 2025 with some notable mergers and acquisitions (M&A), signaling a renewed focus on innovation, pipeline expansion and strategic growth. After a relatively subdued 2024, where companies favored smaller, strategic deals over large-scale acquisitions, major players are now aggressively pursuing deals to strengthen their positions in therapeutic areas such as oncology, neuroscience and cell therapy.
Drug Discovery World podcast
FEBRUARY 20, 2025
In this sponsored DDW Sitting Down With podcast we speak to experts from Lonza and Oxford Nanopore about their collaboration to bring direct mRNA sequencing (including N1-Methyl-pseudouridine) to a regulated environment and establish the new gold standard in sequencing technology. We discuss how nanopore sequencing will be used to perform unbiased identity testing while enabling the simultaneous analyses of multiple critical quality attributes such as integrity (mRNA length and poly-A tail lengt
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
289 
Let's personalize your content